Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus–Induced Cryoglobulinemia Vasculitis

Gastroenterology

Volumn 152, Issue 8, 2017, Pages 2052-2062.e2

  Comarmond, Cloé ^a,b,c   Garrido, Marlène ^a,b   Pol, Stanislas ^d   Desbois, Anne Claire ^a,b,c   Costopoulos, Myrto ^e   Le Garff Tavernier, Magali ^e   Si Ahmed, Si Nafa ^f   Alric, Laurent ^g   Fontaine, Hélène ^d   Bellier, Bertrand ^a,b   Maciejewski, Anna ^a,b   Rosenzwajg, Michelle ^a,b   Klatzmann, David ^a,b   Musset, Lucile ^e   Poynard, Thierry ^e   Cacoub, Patrice ^a,b,c   Saadoun, David ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b Sorbonne Université   (France)

^c Interne DES   (France)

^d Institut Cochin   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f Hôpital d'Orléans   (France)

^g CHU PURPAN   (France)

Author keywords

Immune Regulation; Liver Disease; PDCD1; Response To Treatment

Indexed keywords

ANTIVIRUS AGENT; B CELL ACTIVATING FACTOR RECEPTOR; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR5; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT COMPONENT C4; CRYOGLOBULIN; CYTOKINE; DACLATASVIR; GAMMA INTERFERON; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; RHEUMATOID FACTOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER; BMS-790052; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CD3+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CRYOGLOBULINEMIA; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; FRANCE; HEPATITIS C; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PLASMABLAST; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; VASCULITIS; VIRUS LOAD; VISUAL ANALOG SCALE; B LYMPHOCYTE SUBPOPULATION; BLOOD; CASE CONTROL STUDY; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; HEPATITIS VIRUS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHENOTYPE; T LYMPHOCYTE SUBPOPULATION; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

AGED; ANTIVIRAL AGENTS; B-LYMPHOCYTE SUBSETS; BIOMARKERS; CASE-CONTROL STUDIES; CRYOGLOBULINEMIA; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HEPATITIS VIRUSES; HUMANS; IMIDAZOLES; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; T-LYMPHOCYTE SUBSETS; TIME FACTORS; TREATMENT OUTCOME; VASCULITIS; VIRAL LOAD;

EID: 85020129721     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.02.037     Document Type: Article

References (50)

1. Ramos-Casals, M., Stone, J.H., Cid, M.C., et al. The cryoglobulinaemias. Lancet 379 (2012), 348–360.
2. Cacoub, P., Comarmond, C., Domont, F., et al. Cryoglobulinemia vasculitis. Am J Med 128 (2015), 950–955.
3. Cacoub, P., Comarmond, C., Domont, F., et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 3 (2016), 3–14.
4. Dammacco, F., Sansonno, D., Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 369 (2013), 1035–1045.
5. Charles, E.D., Orloff, M.I.M., Nishiuchi, E., et al. Somatic hypermutations confer rheumatoid factor activity in hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum 65 (2013), 2430–2440.
6. Meltzer, M., Franklin, E.C., Elias, K., et al. Cryoglobulinemia–a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 40 (1966), 837–856.
7. Cacoub, P., Terrier, B., Saadoun, D., Hepatitis C virus-induced vasculitis: therapeutic options. Ann Rheum Dis 73 (2014), 24–30.
8. Saadoun, D., Resche-Rigon, M., Sene, D., et al. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 67 (2008), 1431–1436.
9. Saadoun, D., Resche Rigon, M., Sene, D., et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 116 (2010), 326–334 quiz 504–505.
10. De Vita, S., Quartuccio, L., Isola, M., et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 64 (2012), 843–853.
11. Sneller, M.C., Hu, Z., Langford, C.A., A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 64 (2012), 835–842.
12. Saadoun, D., Thibault, V., Si Ahmed, S.N., et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis 75 (2016), 1777–1782.
13. Sise, M.E., Bloom, A.K., Wisocky, J., et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 63 (2016), 408–417.
14. Gragnani, L., Visentini, M., Fognani, E., et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology 64 (2016), 1473–1482.
15. Landau, D.-A., Rosenzwajg, M., Saadoun, D., et al. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheum 58 (2008), 2897–2907.
16. Boyer, O., Saadoun, D., Abriol, J., et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 103 (2004), 3428–3430.
17. Terrier, B., Joly, F., Vazquez, T., et al. Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J Immunol 187 (2011), 6550–6563.
18. Saadoun, D., Resche-Rigon, M., Thibault, V., et al. Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 54 (2006), 3696–3706.
19. Landau, D.-A., Rosenzwajg, M., Saadoun, D., et al. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders. Ann Rheum Dis 68 (2009), 337–344.
20. Musset, L., Diemert, M.C., Taibi, F., et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 38 (1992), 798–802.
21. Brouet, J.C., Clauvel, J.P., Danon, F., et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57 (1974), 775–788.
22. Garrone, P., Fluckiger, A.-C., Mangeot, P.E., et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med, 3, 2011, 94ra71.
23. Loffreda, S., Muratori, P., Muratori, L., et al. Enhanced monocyte Th1 cytokine production in HCV-infected cryoglobulinemic patients. J Hepatol 38 (2003), 230–236.
24. Wack, A., Soldaini, E., Tseng, C., et al. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol 31 (2001), 166–175.
25. Zhao, L.-J., Zhang, X.-L., Zhao, P., et al. Up-regulation of ERK and p38 MAPK signaling pathways by hepatitis C virus E2 envelope protein in human T lymphoma cell line. J Leukoc Biol 80 (2006), 424–432.
26. Cabrera, R., Tu, Z., Xu, Y., et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40 (2004), 1062–1071.
27. Bolacchi, F., Sinistro, A., Ciaprini, C., et al. Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clin Exp Immunol 144 (2006), 188–196.
28. Boettler, T., Spangenberg, H.C., Neumann-Haefelin, C., et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 79 (2005), 7860–7867.
29. Zhai, N., Chi, X., Li, T., et al. Hepatitis C virus core protein triggers expansion and activation of CD4(+)CD25(+) regulatory T cells in chronic hepatitis C patients. Cell Mol Immunol 12 (2015), 743–749.
30. Terrier, B., Geri, G., Chaara, W., et al. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum 64 (2012), 2001–2011.
31. Ding, Y., Li, J., Yang, P., et al. Interleukin-21 promotes germinal center reaction by skewing the follicular regulatory T cell to follicular helper T cell balance in autoimmune BXD2 mice. Arthritis Rheum 66 (2014), 2601–2612.
32. Spaan, M., Kreefft, K., de Graav, G.N., et al. CD4+ CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses. J Hepatol 62 (2015), 303–310.
33. Foy, E., Li, K., Wang, C., et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300 (2003), 1145–1148.
34. Gragnani, L., Fognani, E., Piluso, A., et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology 61 (2015), 1145–1153.
35. Saadoun, D., Rosenzwajg, M., Joly, F., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365 (2011), 2067–2077.
36. Crotty, S., T follicular helper cell differentiation, function, and roles in disease. Immunity 41 (2014), 529–542.
37. Dai, S., Jia, R., Zhang, X., et al. The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol 290 (2014), 72–79.
38. Sharpe, A.H., Wherry, E.J., Ahmed, R., et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8 (2007), 239–245.
39. Francisco, L.M., Salinas, V.H., Brown, K.E., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206 (2009), 3015–3029.
40. Khan, A.R., Hams, E., Floudas, A., et al. PD-L1(hi) B cells are critical regulators of humoral immunity. Nat Commun, 6, 2015, 5997.
41. Amarnath, S., Mangus, C.W., Wang, J.C.M., et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med, 3, 2011, 111ra120.
42. Hams, E., McCarron, M.J., Amu, S., et al. Blockade of B7-H1 (programmed death ligand 1) enhances humoral immunity by positively regulating the generation of T follicular helper cells. J Immunol 186 (2011), 5648–5655.
43. Sellam, J., Miceli-Richard, C., Gottenberg, J.-E., et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 66 (2007), 790–797.
44. Bolkun, L., Lemancewicz, D., Jablonska, E., et al. BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma. Ann Hematol 93 (2014), 635–644.
45. Krumbholz, M., Specks, U., Wick, M., et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 25 (2005), 298–302.
46. Jiang, C., Loo, W.M., Greenley, E.J., et al. B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus. J Immunol 186 (2011), 6136–6147.
47. Sasaki, Y., Casola, S., Kutok, J.L., et al. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 173 (2004), 2245–2252.
48. Rauch, M., Tussiwand, R., Bosco, N., et al. Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells. PLoS One, 4, 2009, e5456.
49. Ng, L.G., Sutherland, A.P.R., Newton, R., et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 173 (2004), 807–817.
50. Chamberlain, N., Massad, C., Oe, T., et al. Rituximab does not reset defective early B cell tolerance checkpoints. J Clin Invest 126 (2016), 282–287.